Celentyx utilises their NCIP™ application to identify their own candidate drug products for the treatment of immune-mediated disorders.

This has led to the identification of two lead candidate drugs, and both are ready to enter Phase II clinical trials.

For further information and details of partnering opportunities please contact our Commercial Manager Dr Catherine Brady.